

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: NDA 20943



FINAL PRINTED LABELING

VERELAN[®] PM
(verapamil HCl)
Extended-Release Capsules
Controlled-Onset

DESCRIPTION

VERELAN[®] PM (verapamil hydrochloride) is a calcium ion influx inhibitor (slow channel blocker or calcium ion antagonist). VERELAN[®] PM is available for oral administration as a 100 mg hard gelatin capsule (white opaque cap/amethyst body), a 200 mg hard gelatin capsule (amethyst opaque cap/amethyst body), and as a 300 mg hard gelatin capsule (lavender opaque cap/amethyst body). Verapamil is administered as a racemic mixture of the R and S enantiomers.

The structural formulae of the verapamil HCl enantiomers are:



$C_{27}H_{38}N_2O_4 \cdot HCl$ M.W.=491.07

Chemical name: Benzeneacetonitrile, α -[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy- α -(1-methylethyl)-, monohydrochloride, (\pm)-.

Verapamil HCl is an almost white, crystalline powder, practically free of odor, with a bitter taste. It is soluble in water, chloroform and methanol. Verapamil HCl is not structurally related to other cardioactive drugs.

In addition to verapamil HCl the VERELAN[®] PM capsule contains the following inactive ingredients: D&C Red #28, FD & C Blue #1, FD&C red #40, fumaric acid, gelatin, povidone, shellac, silicon dioxide, sodium lauryl sulfate, starch, sugar spheres, talc, and titanium dioxide.

CLINICAL PHARMACOLOGY

Verapamil is a calcium ion influx inhibitor (L-type calcium channel blocker or calcium channel antagonist). Verapamil exerts its pharmacologic effects by selectively inhibiting the transmembrane influx of ionic calcium into arterial smooth muscle as well as in conductile and contractile myocardial cells without altering serum calcium concentrations.

000002

System Components and Performance: VERELAN[®] PM uses the proprietary CODAS[™] (Chronotherapeutic Oral Drug Absorption System) technology, which is designed for bedtime dosing, incorporating a 4 to 5-hour delay in drug delivery. The controlled-onset delivery system results in a maximum plasma concentration (C_{max}) of verapamil in the morning hours. These pellet filled capsules provide for extended-release of the drug in the gastrointestinal tract. The VERELAN[®] PM formulation has been designed to initiate the release of verapamil 4-5 hours after ingestion. This delay is introduced by the level of non-enteric release-controlling polymer applied to drug loaded beads. The release-controlling polymer is a combination of water soluble and water insoluble polymers. As water from the gastrointestinal tract comes into contact with the polymer coated beads, the water soluble polymer slowly dissolves and the drug diffuses through the resulting pores in the coating. The water insoluble polymer continues to act as a barrier, maintaining the controlled release of the drug. The rate of release is essentially independent of pH, posture and food. Multiparticulate systems such as VERELAN[®] PM have been shown to be independent of gastrointestinal motility.

Mechanism of Action

In vitro: Verapamil binding is voltage-dependent with affinity increasing as the vascular smooth muscle membrane potential is reduced. In addition, verapamil binding is frequency dependent and apparent affinity increases with increased frequency of depolarizing stimulus.

The L-type calcium channel is an oligomeric structure consisting of five putative subunits designated alpha-1, alpha-2, beta, tau, and epsilon. Biochemical evidence points to separate binding sites for 1,4-dihydropyridines, phenylalkylamines, and the benzothiazepines (all located on the alpha-1 subunit). Although they share a similar mechanism of action, calcium channel blockers represent three heterogeneous categories of drugs with differing vascular-cardiac selectivity ratios.

Essential hypertension: Verapamil produces its antihypertensive effect by a combination of vascular and cardiac effects. It acts as a vasodilator with selectivity for the arterial portion of the peripheral vasculature. As a result the systemic vascular resistance is reduced and usually without orthostatic hypotension or reflex tachycardia. Bradycardia (rate less than 50 beats/min) is uncommon. During isometric or dynamic exercise verapamil does not alter systolic cardiac function in patients with normal ventricular function.

Verapamil does not alter total serum calcium levels. However, one report has suggested that calcium levels above the normal range may alter the therapeutic effect of verapamil.

Verapamil regularly reduces the total systemic resistance (afterload) against which the heart works both at rest and at a given level of exercise by dilating peripheral arterioles.

000003

Effects in hypertension: VERELAN[®] PM was evaluated in two placebo-controlled, parallel design, double-blind studies of patients with mild to moderate hypertension. In the clinical trials, 413 evaluable patients were randomized to either placebo, 100 mg, 200 mg, 300 mg, or 400 mg and treated for up to 8 weeks. VERELAN[®] PM or placebo was given once daily between 9 pm and 11 pm (nighttime) and blood pressure changes were measured with 36-hour ambulatory blood pressure monitoring (ABPM). The results of these studies demonstrate that VERELAN[®] PM, at 200, 300 and 400 mg, is a consistently and significantly more effective antihypertensive agent than placebo in reducing ambulatory blood pressures. Over this dose range, the placebo-subtracted net decreases in diastolic BP at trough (averaged over 6-10 pm) were dose-related, and ranged from 3.8 to 10.0 mm Hg after 8 weeks of therapy. Although VERELAN[®] PM 100 mg was not effective in reducing diastolic BP at trough when measured by ABPM, efficacy was demonstrated in reducing diastolic BP when measured manually at trough and peak and, from 6 am to 12 noon over 24 hours when measured by ABPM (See *DOSAGE AND ADMINISTRATION* for titration schedule).

There were no apparent treatment differences between patient subgroups of different age (older or younger than 65 years), sex and race. For severity of hypertension, "moderate" hypertensives (mean daytime diastolic BP \geq 105 mm Hg and \leq 114 mm Hg) appeared to respond better than "mild" hypertensives (mean daytime diastolic BP \geq 90 mm Hg and \leq 104 mm Hg). However, sample size for the sub-group comparisons were limited.

Electrophysiologic effects: Electrical activity through the AV node depends, to a significant degree, upon the transmembrane influx of extracellular calcium through the L-type (slow) channel. By decreasing the influx of calcium, verapamil prolongs the effective refractory period within the AV node and slows AV conduction in a rate-related manner.

Normal sinus rhythm is usually not affected, but in patients with sick sinus syndrome, verapamil may interfere with sinus-node impulse generation and may induce sinus arrest or sinoatrial block. Atrioventricular block can occur in patients without pre-existing conduction defects (See *WARNINGS*).

Verapamil does not alter the normal atrial action potential or intraventricular conduction time, but depresses amplitude, velocity of depolarization, and conduction in depressed atrial fibers. Verapamil may shorten the antegrade effective refractory period of the accessory bypass tract. Acceleration of ventricular rate and/or ventricular fibrillation has been reported in patients with atrial flutter or atrial fibrillation and a coexisting accessory AV pathway following administration of verapamil (See *WARNINGS*).

Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis. It is not known whether this action is important at the doses used in man.

000004

Pharmacokinetics and metabolism: Verapamil is administered as a racemic mixture of the R and S enantiomers. The systemic concentrations of R and S enantiomers, as well as overall bioavailability, are dependent upon the route of administration and the rate and extent of release from the dosage forms. Upon oral administration, there is rapid stereoselective biotransformation during the first pass of verapamil through the portal circulation. In a study in 5 subjects with oral immediate-release verapamil, the systemic bioavailability was from 33% to 65% for the R enantiomer and from 13% to 34% for the S enantiomer. Following oral administration of an immediately releasing formulation every 8 hours in 24 subjects, the relative systemic availability of the S enantiomer compared to the R enantiomer was approximately 13% following a single day's administration and approximately 18% following administration to steady-state. The degree of stereoselectivity of metabolism for VERELAN[®] PM was similar to that for the immediately releasing formulation. The R and S enantiomers have differing levels of pharmacologic activity. In studies in animals and humans, the S enantiomer has 8 to 20 times the activity of the R enantiomer in slowing AV conduction. In animal studies, the S enantiomer has 15 to 50 times the activity of the R enantiomer in reducing myocardial contractility in isolated blood-perfused dog papillary muscle, respectively, and twice the effect in reducing peripheral resistance. In isolated septal strip preparations from 5 patients, the S enantiomer was 8 times more potent than the R in reducing myocardial contractility. Dose escalation study data indicate that verapamil concentrations increase disproportionately to dose as measured by relative peak plasma concentrations (C_{max}) or areas under the plasma concentration vs time curves (AUC).

Although some evidence of lack of dose linearity was observed for VERELAN[®] PM, this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of non-linearity.

Pharmacokinetic Characteristics of Verapamil Enantiomers
After Administration of Escalating Doses of VERELAN[®] PM

	ISOMER	200	300	400
Dose Ratio		1	1.5	2
Relative C_{max}	R	1	1.89	2.34
	S	1	1.88	2.5
Relative AUC	R	1	1.67	2.34
	S	1	1.35	2.20

Racemic verapamil is released from VERELAN[®] PM by diffusion following the gradual solubilization of the water soluble polymer. The rate of solubilization of the water soluble polymer produces a lag period in drug release for approximately 4-5 hours. The drug release phase is prolonged with the peak plasma concentration (C_{max}) occurring approximately 11

000005

hours after administration. Trough concentrations occur approximately 4 hours after bedtime dosing while the patient is sleeping. Steady-state pharmacokinetics were determined in healthy volunteers. Steady-state concentration is achieved by day 5 of dosing.

In healthy volunteers, following administration of VERELAN® PM (200 mg per day), steady-state pharmacokinetics of the R and S enantiomers of verapamil is as follows: Mean C_{max} of the R isomer was 77.8 ng/ml and 16.8 ng/ml for the S isomer; AUC (0-24h) of the R isomer was 1037 ng.h/ml and 195 ng.h/ml for the S isomer.

In general, bioavailability of verapamil is higher and half life longer in older (>65 yrs) subjects. Lean body weight also affects its pharmacokinetics inversely. It was not possible to observe a gender difference in the clinical trials of VERELAN® PM due to the small sample size. However, there are conflicting data in the literature suggesting that verapamil clearance decreased with age in women to a greater degree than in men.

Consumption of a high fat meal just prior to dosing in the morning had no effect on the extent of absorption and a modest effect on the rate of absorption from VERELAN® PM. The rate of absorption was not affected by whether the volunteers were supine two hours after night-time dosing or non-supine for four hours following morning dosing. Administering VERELAN® PM in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.

Orally administered verapamil undergoes extensive metabolism in the liver. Verapamil is metabolized by O-demethylation (25%) and N-dealkylation (40%), and is subject to pre-systemic hepatic metabolism with elimination of up to 80% of the dose. The metabolism is mediated by hepatic cytochrome P_{450} , and animal studies have implied that the mono-oxygenase is the specific isoenzyme of the P_{450} family. Thirteen metabolites have been identified in urine. Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug. For VERELAN® PM, the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations. The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil. Approximately 70% of an administered dose is excreted as metabolites in the urine and 16% or more in the feces within 5 days. About 3% to 4% is excreted in the urine as unchanged drug.

R verapamil is 94% bound to plasma albumin, while S verapamil is 88% bound. In addition, R verapamil is 92% and S verapamil 86% bound to alpha-1 acid glycoprotein. In patients with hepatic insufficiency, metabolism of immediate-release verapamil is delayed and elimination half-life prolonged up to 14 to 16 hours because of the extensive hepatic metabolism (See *PRECAUTIONS*). In addition, in these patients there is a reduced first pass effect, and verapamil is more bioavailable. Verapamil clearance values suggest that patients with liver dysfunction may attain therapeutic verapamil plasma concentrations with one third of the oral daily dose required for patients with normal liver function.

000006

After four weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.

Hemodynamics: Verapamil reduces afterload and myocardial contractility. In most patients, including those with organic cardiac disease, the negative inotropic action of verapamil is countered by reduction of afterload and cardiac index remains unchanged. During isometric or dynamic exercise, verapamil does not alter systolic cardiac function in patients with normal ventricular function. Improved left ventricular diastolic function in patients with IHSS and those with coronary heart disease has also been observed with verapamil. In patients with severe left ventricular dysfunction (e.g., pulmonary wedge pressure above 20 mm Hg or ejection fraction less than 30%), or in patients taking beta-adrenergic blocking agents or other cardiodepressant drugs, deterioration of ventricular function may occur (See *Drug Interactions*).

Pulmonary function: Verapamil does not induce bronchoconstriction and, hence, does not impair ventilatory function.

Verapamil has been shown to have either a neutral or relaxant effect on bronchial smooth muscle.

INDICATIONS AND USAGE

VERELAN[®] PM is indicated for the management of essential hypertension.

CONTRAINDICATIONS

Verapamil is contraindicated in:

1. Severe left ventricular dysfunction (See *WARNINGS*).
2. Hypotension (less than 90 mm Hg systolic pressure) or cardiogenic shock.
3. Sick sinus syndrome (except in patients with a functioning artificial ventricular pacemaker).
4. Second- or third-degree AV block (except in patients with a functioning artificial ventricular pacemaker).
5. Patients with atrial flutter or atrial fibrillation and an accessory bypass tract (e.g., Wolff-Parkinson-White, Lown-Ganong-Levine syndromes) (See *WARNINGS*).
6. Patients with known hypersensitivity to verapamil hydrochloride.

000007

WARNINGS

Heart failure: Verapamil has a negative inotropic effect which, in most patients, is compensated by its afterload reduction (decreased systemic vascular resistance) properties without a net impairment of ventricular performance. In previous clinical experience with 4,954 patients primarily with immediate-release verapamil, 87 (1.8%) developed congestive heart failure or pulmonary edema. Verapamil should be avoided in patients with severe left ventricular dysfunction (e.g., ejection fraction less than 30% or moderate to severe symptoms of cardiac failure) and in patients with any degree of ventricular dysfunction if they are receiving a beta-adrenergic blocker (See *Drug Interactions*). Patients with milder ventricular dysfunction should, if possible, be controlled with optimum doses of digitalis and/or diuretics before verapamil treatment is started (See *PRECAUTIONS, Drug Interactions, Digitalis*).

Hypotension: Occasionally, the pharmacologic action of verapamil may produce a decrease in blood pressure below normal levels which may result in dizziness or symptomatic hypotension. The incidence of hypotension observed in 4,954 patients enrolled in clinical trials was 2.5%. In hypertensive patients, decreases in blood pressure below normal are unusual. Tilt table testing (60 degrees) was not able to induce orthostatic hypotension. In clinical studies of VERELAN[®] PM, 1.7% of the patients developed significant hypotension.

Elevated liver enzymes: Elevations of transaminases with and without concomitant elevations in alkaline phosphatase and bilirubin have been reported. Such elevations have sometimes been transient and may disappear even in the face of continued verapamil treatment.

Several cases of hepatocellular injury related to verapamil have been proven by rechallenge; half of these had clinical symptoms (malaise, fever, and/or right upper quadrant pain) in addition to elevations of SGOT, SGPT and alkaline phosphatase. Periodic monitoring of liver function in patients receiving verapamil is therefore prudent.

Accessory bypass tract (Wolff-Parkinson-White or Lown-Ganong-Levine): Some patients with paroxysmal and/or chronic atrial flutter or atrial fibrillation and a coexisting accessory AV pathway have developed increased antegrade conduction across the accessory pathway bypassing the AV node, producing a very rapid ventricular response or ventricular fibrillation after receiving intravenous verapamil (or digitalis). Although a risk of this occurring with oral verapamil has not been established, such patients receiving oral verapamil may be at risk and its use in these patients is contraindicated (See *CONTRAINDICATIONS*).

Treatment is usually DC-cardioversion. Cardioversion has been used safely and effectively after oral verapamil.

000008

Atrioventricular block

The effect of verapamil on AV conduction and the SA node may lead to asymptomatic first-degree AV block and transient bradycardia, sometimes accompanied by nodal escape rhythms. PR interval prolongation is correlated with verapamil plasma concentrations, especially during the early titration phase of therapy. Higher degrees of AV block, however, were infrequently (0.8%) observed in previous verapamil clinical trials.

Marked first-degree block or progressive development to second- or third-degree AV block requires a reduction in dosage or, in rare instances, discontinuation of verapamil and institution of appropriate therapy depending upon the clinical situation.

Patients with hypertrophic cardiomyopathy (IHSS)

In 120 patients with hypertrophic cardiomyopathy (most of them refractory or intolerant to propranolol) who received therapy with verapamil at doses up to 720 mg/day, a variety of serious adverse effects were seen. Three patients died in pulmonary edema; all had severe left ventricular outflow obstruction and a past history of left ventricular dysfunction. Eight other patients had pulmonary edema and/or severe hypotension; abnormally high (over 20 mm Hg) pulmonary capillary wedge pressure and a marked left ventricular outflow obstruction were present in most of these patients. Concomitant administration of quinidine (See *Drug Interactions*) preceded the severe hypotension in 3 of the 8 patients (2 of whom developed pulmonary edema). Sinus bradycardia occurred in 11% of the patients, second-degree AV block in 4% and sinus arrest in 2%. It must be appreciated that this group of patients had a serious disease with a high mortality rate. Most adverse effects responded well to dose reduction and only rarely did verapamil have to be discontinued.

PRECAUTIONS

THE CONTENTS OF THE VERELAN[®] PM CAPSULE SHOULD NOT BE CRUSHED OR CHEWED.

General

Use in patients with impaired hepatic function: Since verapamil is highly metabolized by the liver, it should be administered cautiously to patients with impaired hepatic function. Severe liver dysfunction prolongs the elimination half-life of immediate-release verapamil to about 14 to 16 hours; hence, approximately 30% of the dose given to patients with normal liver function should be administered to these patients. Careful monitoring for abnormal prolongation of the PR interval or other signs of excessive pharmacologic effects (See *OVERDOSAGE*) should be carried out.

Use in patients with attenuated (decreased) neuromuscular transmission: It has been reported that verapamil decreases neuromuscular transmission in patients with Duchenne's muscular dystrophy, and that verapamil prolongs recovery from the neuromuscular blocking agent vecuronium. It may be necessary to decrease the dosage of verapamil when it is administered to patients with attenuated neuromuscular transmission.

000009

Use in patients with impaired renal function: About 70% of an administered dose of verapamil is excreted as metabolites in the urine. Until further data are available, verapamil should be administered cautiously to patients with impaired renal function. These patients should be carefully monitored for abnormal prolongation of the PR interval or other signs of overdosage (See *OVERDOSAGE*).

Drug Interactions

Verapamil undergoes biotransformation by predominantly CYP3A4, however CYP1A2 and members of the CYP2C subfamily are involved in its metabolism. Coadministration of verapamil with other drugs metabolized by the above-mentioned enzymes may alter the bioavailability of either verapamil and/or the other drugs. Therefore, coadministration of narrow therapeutic index drugs with similar metabolic pathways as verapamil should be carefully monitored. Similarly, verapamil plasma levels in patients with hepatic dysfunction should be carefully monitored, due to decreased clearance of verapamil in these patients.

Alcohol: Verapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.

Antineoplastic agents: Verapamil can increase the efficacy of doxorubicin both in tissue culture systems and in patients. It raises the serum doxorubicin levels. The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens. Concomitant administration of R verapamil can decrease the clearance of paclitaxel.

Aspirin: In a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.

Beta blockers: Concomitant therapy with beta-adrenergic blockers and verapamil may result in additive negative effects on heart rate, atrioventricular conduction, and/or cardiac contractility. The combination of extended-release verapamil and beta-adrenergic blocking agents has not been studied. However, there have been reports of excess bradycardia and AV block, including complete heart block, when the combination has been used for the treatment of hypertension. For hypertensive patients, the risk of combined therapy may outweigh the potential benefits. The combination should be used only with caution and close monitoring.

Asymptomatic bradycardia (36 beats/min) with a wandering atrial pacemaker has been observed in a patient receiving concomitant timolol (a beta-adrenergic blocker) eyedrops and oral verapamil.

A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil. A variable effect has been seen when verapamil and atenolol were given together.

000010

Digitalis: Clinical use of verapamil in digitalized patients has shown the combination to be well tolerated if digoxin doses are properly adjusted. However, chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity. In patients with hepatic cirrhosis the influence of verapamil on digoxin kinetics is magnified. Verapamil may reduce total body clearance of digitoxin by 27% and 29%, respectively. Maintenance and digitalization doses should be reduced when verapamil is administered, and the patient should be reassessed to avoid over- or underdigitalization. Whenever overdigitalization is suspected, the daily dose of digoxin should be reduced or temporarily discontinued. On discontinuation of verapamil use, the patient should be reassessed to avoid underdigitalization. In previous clinical trials with other verapamil formulations related to the control of ventricular response in digitalized patients who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.

Antihypertensive agents

Verapamil administered concomitantly with oral antihypertensive agents (e.g., vasodilators, angiotensin-converting enzyme inhibitors, diuretics, beta blockers) will usually have an additive effect on lowering blood pressure. Patients receiving these combinations should be appropriately monitored. Concomitant use of agents that attenuate alpha-adrenergic function with verapamil may result in reduction in blood pressure that is excessive in some patients. Such an effect was observed in one study following the concomitant administration of verapamil and prazosin.

Antiarrhythmic agents

Disopyramide: Until data on possible interactions between verapamil and disopyramide are obtained, disopyramide should not be administered within 48 hours before or 24 hours after verapamil administration.

Flecainide: A study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction, and repolarization. Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction.

Quinidine: In a small number of patients with hypertrophic cardiomyopathy (IHSS), concomitant use of verapamil and quinidine resulted in significant hypotension. Until further data are obtained, combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy should probably be avoided.

The electrophysiological effects of quinidine and verapamil on AV conduction were studied in 8 patients. Verapamil significantly counteracted the effects of quinidine on AV conduction. There has been a report of increased quinidine levels during verapamil therapy.

Other

000011

Nitrates: Verapamil has been given concomitantly with short- and long-acting nitrates without any undesirable drug interactions. The pharmacologic profile of both drugs and the clinical experience suggest beneficial interactions.

Cimetidine: The interaction between cimetidine and chronically administered verapamil has not been studied. Variable results on clearance have been obtained in acute studies of healthy volunteers; clearance of verapamil was either reduced or unchanged.

Lithium: Increased sensitivity to the effects of lithium (neurotoxicity) has been reported during concomitant verapamil-lithium therapy with either no change or an increase in serum lithium levels. However, the addition of verapamil has also resulted in the lowering of serum lithium levels in patients receiving chronic stable oral lithium. Patients receiving both drugs must be monitored carefully.

Carbamazepine: Verapamil therapy may increase carbamazepine concentrations during combined therapy. This may produce carbamazepine side effects such as diplopia, headache, ataxia, or dizziness.

Rifampin: Therapy with rifampin may markedly reduce oral verapamil bioavailability.

Phenobarbital: Phenobarbital therapy may increase verapamil clearance.

Cyclosporin: Verapamil therapy may increase serum levels of cyclosporin.

Theophylline: Verapamil may inhibit the clearance and increase the plasma levels of theophylline.

Inhalation anesthetics: Animal experiments have shown that inhalation anesthetics depress cardiovascular activity by decreasing the inward movement of calcium ions. When used concomitantly, inhalation anesthetics and calcium antagonists, such as verapamil, should each be titrated carefully to avoid excessive cardiovascular depression.

Neuromuscular blocking agents: Clinical data and animal studies suggest that verapamil may potentiate the activity of neuromuscular blocking agents (curare-like and depolarizing). It may be necessary to decrease the dose of verapamil and/or the dose of the neuromuscular blocking agent when the drugs are used concomitantly.

Carcinogenesis, Mutagenesis, Impairment of Fertility

An 18-month toxicity study in rats, at a low multiple (6-fold) of the maximum recommended human dose, and not the maximum tolerated dose, did not suggest a tumorigenic potential. There was no evidence of a carcinogenic potential of verapamil administered in the diet of rats for two years at doses of 10, 35 and 120 mg/kg/day or approximately 1.3, 4.4 and 15 times, respectively, the maximum recommended human daily dose (400 mg/day or 8 mg/kg/day).

000012

Verapamil was not mutagenic in the Ames test in 5 test strains at 3 mg per plate, with or without metabolic activation.

Studies in female rats at daily dietary doses up to 6.9 times (55 mg/kg/day) the maximum recommended human dose did not show impaired fertility. Effects on male fertility have not been determined.

Pregnancy

Pregnancy Category C. Reproduction studies have been performed in rabbits and rats at oral doses up to 1.9 (15 mg/kg/day) and 7.5 (60 mg/kg/day) times the human oral daily dose, respectively, and have revealed no evidence of teratogenicity. In the rat, however, this multiple of the human dose was embryocidal and retarded fetal growth and development, probably because of adverse maternal effects reflected in reduced weight gains of the dams. This oral dose has also been shown to cause hypotension in rats. There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Verapamil crosses the placental barrier and can be detected in umbilical vein blood at delivery.

Labor and Delivery

It is not known whether the use of verapamil during labor or delivery has immediate or delayed adverse effects on the fetus, or whether it prolongs the duration of labor or increases the need for forceps delivery or other obstetric intervention. Such adverse experiences have not been reported in the literature, despite a long history of use of verapamil in Europe in the treatment of cardiac side effects of beta-adrenergic agonist agents used to treat premature labor.

Nursing Mothers

Verapamil is excreted in human milk. Because of the potential for adverse reactions in nursing infants from verapamil, nursing should be discontinued while verapamil is administered.

Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

Geriatric Use

Clinical studies of VERELAN® PM were not adequate to determine if subjects aged 65 or over respond differently from younger patients. Other reported clinical experience has not identified differences in response between the elderly and younger patients; however, greater sensitivity to VERELAN® PM by some older individuals cannot be ruled out.

Aging may affect the pharmacokinetics of verapamil. Elimination half-life may be prolonged in the elderly (See *CLINICAL PHARMACOLOGY, Pharmacokinetics and metabolism*).

Verapamil is highly metabolized by the liver, and about 70% of the administered dose is excreted as metabolites in the urine. Clinical circumstances, some of which may be more

000013

common in the elderly, such as hepatic or renal impairment, should be considered (See *PRECAUTIONS, General*). In general, lower initial doses of VERELAN[®] PM may be warranted in the elderly (See *DOSAGE AND ADMINISTRATION, Essential Hypertension*).

Animal Pharmacology and/or Animal Toxicology

In chronic animal toxicology studies verapamil caused lenticular and/or suture line changes at 30 mg/kg/day or greater and frank cataracts at 62.5 mg/kg/day or greater in the beagle dog but not in the rat. Development of cataracts due to verapamil has not been reported in man.

ADVERSE REACTIONS

Serious adverse reactions are uncommon when verapamil therapy is initiated with upward dose titration within the recommended single and total daily dose.

The following reactions to orally administered VERELAN[®] PM occurred at rates of 2.0% or greater or occurred at lower rates but appeared to be drug-related in clinical trials in hypertension.

	Placebo	All Doses Studied
	N = 116	N = 297
	%	%
Headache	11.2	12.1
Infection	6.9	12.1*
Constipation	0.9	8.8*
Flu Syndrome	2.6	3.7
Peripheral edema	0.9	3.7
Dizziness	0.9	3.0
Pharyngitis	2.6	3.0
Sinusitis	2.6	3.0
Dyspepsia	1.7	2.7
Rhinitis	2.6	2.7
Diarrhea	1.7	2.4
Pain	1.7	2.4
Rash	2.6	2.4
Asthenia	3.4	2.0
ECG Abnormal	3.4	2.0
Hypertension	2.0	1.7
Edema	0.0	1.7
Nausea	0.0	1.7
Accidental Injury	0.0	1.5

000014

*Infection, primarily upper respiratory infection (URI) and unrelated to study medication. Constipation was typically mild and easily manageable. At the usual once-daily dose of 200 mg, the observed incidence of constipation was 3.9%.

See *WARNINGS* for discussion of heart failure, hypotension, elevated liver enzymes, AV block, and rapid ventricular response. Reversible (upon discontinuation of verapamil) non-obstructive, paralytic ileus has been infrequently reported in association with the use of verapamil.

In previous experience with other formulations of verapamil (N=4,954) the following reactions have occurred at rates greater than 1.0% or occurred at lower rates but appeared clearly drug related in clinical trials in 4,954 patients.

Constipation	7.3%
Dizziness	3.3%
Nausea	2.7%
Hypotension	2.5%
Headache	2.2%
Edema	1.9%
CHF/Pulmonary Edema	1.8%
Fatigue	1.7%
Bradycardia (HR<50/min)	1.4%
Rash	1.2%
AV block (total 1 ^o , 2 ^o , 3 ^o)	1.2%
AV block (2 ^o and 3 ^o)	0.8%
Flushing	0.6%
Elevated Liver Enzymes (See <i>WARNINGS</i>)	

In clinical trials related to the control of ventricular response in digitalized patients who had atrial fibrillation or atrial flutter, ventricular rate below 50/min at rest occurred in 15% of patients and asymptomatic hypotension occurred in 5% of patients.

The following reactions, reported with orally administered verapamil in 2.0% or less of patients, occurred under conditions (open trials, marketing experience) where a causal relationship is uncertain; they are listed to alert the physician to a possible relationship:

Cardiovascular: angina pectoris, atrioventricular dissociation, chest pain, claudication, myocardial infarction, palpitations, purpura (vasculitis), syncope.

Digestive System: diarrhea, dry mouth, gastrointestinal distress, gingival hyperplasia.

Hemic and Lymphatic: ecchymosis or bruising.

000015

Nervous System: cerebrovascular accident, confusion, equilibrium disorders, insomnia, muscle cramps, paresthesia, psychotic symptoms, shakiness, somnolence.

Respiratory: dyspnea.

Skin: arthralgia and rash, exanthema, hair loss, hyperkeratosis, macules, sweating, urticaria, Stevens-Johnson syndrome, erythema multiforme.

Special Senses: blurred vision, tinnitus.

Urogenital: gynecomastia, galactorrhea/hyperprolactinemia, impotence, increased urination, spotty menstruation.

Other: allergy aggravated.

Treatment of Acute Cardiovascular Adverse Reactions

The frequency of cardiovascular adverse reactions that require therapy is rare; hence, experience with their treatment is limited. Whenever severe hypotension or complete AV block occurs following oral administration of verapamil, the appropriate emergency measures should be applied immediately; e.g., intravenously administered norepinephrine bitartrate, atropine sulfate, isoproterenol HCl (all in the usual doses), or calcium gluconate (10% solution). In patients with hypertrophic cardiomyopathy (IHSS), alpha-adrenergic agents (phenylephrine HCl, metaraminol bitartrate, or methoxamine HCl) should be used to maintain blood pressure, and isoproterenol and norepinephrine should be avoided. If further support is necessary, inotropic agents (dopamine HCl or dobutamine HCl) may be administered. Actual treatment and dosage should depend on the severity of the clinical situation and the judgment and experience of the treating physician.

OVERDOSAGE

There is no specific antidote for verapamil overdosage; treatment should be supportive. Delayed pharmacodynamic consequences may occur with sustained-release formulations, and patients should be observed for at least 48 hours, preferably under continuous hospital care. Reported effects include hypotension, bradycardia, cardiac conduction defects, arrhythmias, hyperglycemia, and decreased mental status. In addition, there have been literature reports of noncardiogenic pulmonary edema in patients taking large overdoses of verapamil (up to approximately 9g).

In acute overdosage, gastrointestinal decontamination with cathartics and whole bowel irrigation should be considered. Calcium, inotropes (i.e., isoproterenol HCl, dopamine HCl, and glucagon), atropine sulfate, vasopressors (i.e., norepinephrine, and epinephrine), and cardiac pacing have been used with variable results to reverse hypotension and myocardial depression. In a few reported cases, overdose with calcium channel blockers that was initially refractory to atropine became more responsive to this treatment when the patients received large doses (close to 1 gram/hour for more than 24 hours) of calcium chloride.

000016

Calcium chloride is preferred to calcium gluconate since it provides 3 times more calcium per volume. Asystole should be handled by the usual measures including cardiopulmonary resuscitation. Verapamil cannot be removed by hemodialysis.

DOSAGE AND ADMINISTRATION

Essential Hypertension

VERELAN[®] PM should be administered once daily at bedtime. Clinical trials studied doses of 100 mg, 200 mg, 300 mg and 400 mg. The usual daily dose of extended-release VERELAN[®] PM in clinical trials has been 200 mg given by mouth once daily at bedtime. In rare instances, initial doses of 100 mg a day may be warranted in patients who have an increased response to verapamil [e.g. patients with impaired renal function (See *PRECAUTIONS*), impaired hepatic function, elderly, small people, etc.]. Upward titration should be based on therapeutic efficacy and safety evaluated approximately 24 hours after dosing. The antihypertensive effects of VERELAN[®] PM are evident within the first week of therapy.

If an adequate response is not obtained with 200 mg of VERELAN[®] PM, the dose may be titrated upward in the following manner:

- a) 300 mg each evening
- b) 400 mg each evening (2 x 200 mg)

When VERELAN[®] PM is administered at bedtime, office evaluation of blood pressure during morning and early afternoon hours is essentially a measure of peak effect. The usual evaluation of trough effect, which sometimes might be needed to evaluate the appropriateness of any given dose of VERELAN[®] PM would be just prior to bedtime.

As with immediate-release and sustained-release verapamil, dosages of VERELAN[®] PM capsules should be individualized and titration may be needed in some patients.

HOW SUPPLIED

VERELAN[®] PM (verapamil HCl) extended-release pellet filled capsules are supplied in three dosage strengths:

100 mg: Two piece size 2 hard gelatin capsule, white opaque cap imprinted SCHWARZ/4085 and amethyst body imprinted with 100 mg. Product identification printed in black ink, supplied as follows:

NDC 0091-4085-01 Bottle of 100s

200 mg: Two piece size 0 hard gelatin capsule, amethyst opaque cap imprinted SCHWARZ/4086 and amethyst body imprinted with 200 mg. Product identification printed in black ink, supplied as follows:

NDC 0091-4086-01 Bottle of 100s

000017

VERELAN[®]PM (verapamil hydrochloride) Extended-Release Capsules 100 mg, 200 mg and 300 mg
NDA #20-943: Final Draft Labeling
ELAN PHARMACEUTICAL RESEARCH CORPORATION

300 mg: Two piece size 00 hard gelatin capsule, lavender opaque cap imprinted SCHWARZ/4087 and amethyst body imprinted 300 mg. Product identification printed in black ink, supplied as follows:
NDC 0091-4087-01 Bottle of 100s

Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F). [See USP Controlled Room Temperature]. Protect from moisture.

Dispense in tight, light-resistant container as defined in USP.

Rx only

Manufactured for:

SCHWARZ
P H A R M A
Milwaukee, WI 53201



by: ELAN PHARMA, INC.
Gainesville, GA 30504

PC3810 11/98
Printed in USA

000018

FINAL DRAFT

CONTAINER LABELS

100 MG, 200 MG, 300 MG

000020

DRAFT CONTAINER LABEL (100 CAPSULES)

<p>NDC 0091-4085-01 VERELAN[®] PM VERAPAMIL HCl EXTENDED-RELEASE CAPSULES 100 MG CONTROLLED-ONSET EACH CAPSULE CONTAINS: 100 mg/Verapamil Hydrochloride, USP</p> <p style="text-align: right;">Rx Only</p> <p>100 CAPSULES</p> <hr/>	<p>USUAL ADULT DOSAGE: See accompanying package insert. Dispense in tight, light-resistant container as defined in USP. This package not for household dispensing.</p> <p>Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [See USP Controlled Room Temperature] Protect from moisture.</p> <p>Manufactured for</p> <p>SCHWARZ P H A R M A Milwaukee, WI 53201</p> <p>By ELAN PHARMA, INC. Pharmaceutical Division, Gainesville, GA 30504</p> <p>Control No.</p> <p>Exp. Date</p>
---	---

000021

DRAFT CONTAINER LABEL (100 CAPSULES)

<p>NDC 0091-4086-01 VERELAN[®] PM VERAPAMIL HCl EXTENDED-RELEASE CAPSULES 200 MG CONTROLLED-ONSET EACH CAPSULE CONTAINS: 200 mg/Verapamil Hydrochloride, USP</p> <p style="text-align: right;">Rx Only</p> <p>100 CAPSULES</p> <hr/>	<p>USUAL ADULT DOSAGE: See accompanying package insert. Dispense in tight, light-resistant container as defined in USP. This package not for household dispensing.</p> <p>Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [See USP Controlled Room Temperature]</p> <p>Protect from moisture.</p> <p>Manufactured for</p> <p>SCHWARZ P H A R M A Milwaukee, WI 53201</p> <p>By ELAN PHARMA, INC. Pharmaceutical Division, Gainesville, GA 30504</p> <p>Control No.</p> <p>Exp. Date</p>
---	--

000022

DRAFT CONTAINER LABEL (100 CAPSULES)

<p>NDC 0091-4087-01 VERELAN[®] PM VERAPAMIL HCl EXTENDED-RELEASE CAPSULES 300 MG CONTROLLED-ONSET EACH CAPSULE CONTAINS: 300 mg/Verapamil Hydrochloride, USP</p> <p style="text-align: right;">Rx Only</p> <p>100 CAPSULES</p> <hr/>	<p>USUAL ADULT DOSAGE: See accompanying package insert. Dispense in tight, light-resistant container as defined in USP. This package not for household dispensing.</p> <p>Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [See USP Controlled Room Temperature]</p> <p>Protect from moisture.</p> <p>Manufactured for</p> <p>SCHWARZ P H A R M A Milwaukee, WI 53201</p> <p>By ELAN PHARMA, INC. Pharmaceutical Division, Gainesville, GA 30504</p> <p>Control No.</p> <p>Exp. Date</p>
---	---

000023

FINAL DRAFT LABELING

PHYSICIAN SAMPLES

100 MG, 200 MG, 300 MG

000024

FOIL BLISTER LABELING

000025

Physician Sample

NDC 0091-4085-99

VERELAN[®] PM
Verapamil HCl
EXTENDED-RELEASE CAPSULES
100 mg
CONTROLLED-ONSET

 Manufactured for SCHWARZ PHARMA, INC.
By ELAN PHARMA, INC
Pharmaceutical Division, Gainesville, GA 30504

©1998 Elan Pharma, Inc Printed in USA REV XXX

Control No.	Exp. Date
-------------	-----------

Front Panel

SAMPLE- NOT TO BE SOLD 5 CAPSULES

Rx only
DOSAGE: As prescribed by the physician.
Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F)
[See USP Controlled Room Temperature]
Protect from moisture.
REV XXX

Back Panel

000026

Physician Sample

NDC 0091-4086-99

VERELAN[®] PM
Verapamil HCl
EXTENDED-RELEASE CAPSULES
200 mg
CONTROLLED-ONSET

 Manufactured for SCHWARZ PHARMA, INC
By ELAN PHARMA, INC
Pharmaceutical Division, Gainesville, GA 30504

©1998 Elan Pharma, Inc Printed in USA REV XXX

Control No.	Exp. Date
-------------	-----------

Front Panel

SAMPLE- NOT TO BE SOLD 5 CAPSULES

Rx only
DOSAGE: As prescribed by the physician.
Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F)
[See USP Controlled Room Temperature]
Protect from moisture.
REV XXX

Back Panel

000027

Physician Sample

NDC 0091-4087-99

VERELAN[®] PM
Verapamil HCl
EXTENDED-RELEASE CAPSULES
300 mg
CONTROLLED-ONSET

 Manufactured for SCHWARZ PHARMA, INC.
By ELAN PHARMA, INC
Pharmaceutical Division, Gainesville, GA 30504

©1998 Elan Pharma, Inc Printed in USA REV XXX

Control No.	Exp. Date
-------------	-----------

Front Panel

SAMPLE- NOT TO BE SOLD 5 CAPSULES

Rx only
DOSAGE: As prescribed by the physician.
Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F)
[See USP Controlled Room Temperature]
Protect from moisture.
REV XXX

Back Panel

000028

OUTER CARTON LABELING

000029

VERELAN[®] PM 100 mg
Verapamil HCl EXTENDED-RELEASE CAPSULES

VERELAN[®] PM
Verapamil HCl

EXTENDED-RELEASE CAPSULES
100 mg

Controlled-Onset

Professional Sample

5 Capsules

VERELAN[®] PM 100 mg
Verapamil HCl
EXTENDED-RELEASE CAPSULES

VERELAN[®] PM 100 mg
Verapamil HCl EXTENDED-RELEASE CAPSULES

CR2816 10/98

Elan Pharma, Inc.
Pharmaceutical Division
Gainesville, GA 30504



Manufactured By:

SCHWABZ PHARMA, INC. (logos)
MILWAUKEE, WI 53201

Protect from moisture.

Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F). (See USP Controlled Room Temperature).

100 mg
EXTENDED-RELEASE CAPSULES
Controlled-Onset

VERELAN[®] PM
Verapamil HCl

Control No.
Exp. Date

VERELAN[®] PM 100 mg
Verapamil HCl
EXTENDED-RELEASE CAPSULES

000030

VERELAN[®] PM 200 mg
Verapamil HCl EXTENDED-RELEASE CAPSULES

VERELAN[®] PM
Verapamil HCl

EXTENDED-RELEASE CAPSULES
200 mg

Controlled-Onset

Professional Sample 5 Capsules

VERELAN[®] PM 200 mg
Verapamil HCl
EXTENDED-RELEASE CAPSULES

VERELAN[®] PM 200 mg
Verapamil HCl EXTENDED-RELEASE CAPSULES

Control No.
Exp. Date

VERELAN[®] PM 200 mg
Verapamil HCl
EXTENDED-RELEASE CAPSULES

CR3816 10/98

Eli Lilly and Company
Pharmaceutical Division
Greenfield, IN 46030



Manufactured By:

SCHWAB PHARMA, INC. (log)
Milwaukee, WI 53201

Protect from moisture.


Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F). (See USP Controlled Room Temperature).

For Only

VERELAN[®] PM 200 mg
EXTENDED-RELEASE CAPSULES
Controlled-Onset

VERELAN[®] PM
Verapamil HCl

000031



VERELAN[®] PM 300 mg
Verapamil HCl EXTENDED-RELEASE CAPSULES

VERELAN[®] PM
Verapamil HCl

EXTENDED-RELEASE CAPSULES
300 mg

Controlled-Onset

Professional Sample 5 Capsules

VERELAN[®] PM 300 mg
Verapamil HCl EXTENDED-RELEASE CAPSULES

Control No.
Exp. Date

VERELAN[®] PM 300 mg
Verapamil HCl
EXTENDED-RELEASE CAPSULES

Manufactured By:
Egan Pharmaceuticals, Inc.
Gainesville, GA 30504
CR3816 10/98

Manufactured for:
SCHWARZ PHARMA, INC. (logos)
Milwaukee, WI 53201

Rx Only
Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F). (See USP Controlled Room Temperature).
Protect from moisture.

VERELAN[®] PM
Verapamil HCl
EXTENDED-RELEASE CAPSULES
300 mg
Controlled-Onset


VERELAN[®] PM 300 mg
Verapamil HCl
EXTENDED-RELEASE CAPSULES

000032

VERELAN[®]PM (verapamil hydrochloride) Extended-Release Capsules 100 mg, 200 mg and 300 mg
NDA #20-943: Final Draft Labeling
ELAN PHARMACEUTICAL RESEARCH CORPORATION

SAMPLE TRAY LABELING

000033



VERELAN® PM

Verapamil HCl

EXTENDED-RELEASE CAPSULES

100 mg

CONTROLLED-ONSET

Side Panel

VERELAN® PM

Verapamil HCl


EXTENDED-RELEASE CAPSULES

100 mg

Front Panel


000034

Top Flap



VERELAN® PM
(Verapamil HCl)
EXTENDED-RELEASE CAPSULES
100 mg
Controlled-Onset

Professional Sample
NDC 0091-485-99
5-1 x 5 Capsules



VERELAN® PM
Verapamil HCl
EXTENDED-RELEASE CAPSULES
100 mg
CONTROLLED-ONSET

Rx Only
Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F)
[See USP Controlled Room Temperature]
Protect from moisture.
See package insert for further information.
Manufactured for:
SCHWARZ PHARMA, INC. (logo)
Milwaukee, WI 53201


By:
 Elan Pharma, Inc.
Pharmaceutical Division
Gainesville, GA 30504

CR3815 10/98
©1998, Schwarz Pharma, Inc., Milwaukee WI 53201, USA

Side Panel

Back Panel

000035



VERELAN® PM
Verapamil HCl
EXTENDED-RELEASE CAPSULES
200 mg
CONTROLLED-ONSET

Side Panel

VERELAN® PM
Verapamil HCl
EXTENDED-RELEASE CAPSULES
200 mg

Front Panel

000036

Top Flap

VERELAN® PM
(Verapamil HCl)
EXTENDED-RELEASE CAPSULES
200 mg
Controlled-Onset

NDC 0091-1600-99
5-1 x 5 Capsules

Professional Sample

VERELAN® PM

Verapamil HCl

EXTENDED-RELEASE CAPSULES

200 mg

CONTROLLED-ONSET

Rx Only

Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F)

[See USP Controlled Room Temperature]

Protect from moisture.

See package insert for further information.

Manufactured for:

SCHWARZ PHARMA, INC. (logo)

Milwaukee, WI 53201

By:



Elan Pharma, Inc.
Pharmaceutical Division
Gainesville, GA 30504


CR3815 1098

©1998, Schwarz Pharma, Inc., Milwaukee WI 53201, USA

Side Panel

Back Panel

000037



VERELAN® PM
Verapamil HCl
EXTENDED-RELEASE CAPSULES
300 mg
CONTROLLED-ONSET

Side Panel

VERELAN® PM
Verapamil HCl
EXTENDED-RELEASE CAPSULES
300 mg

Front Panel

000038

Top Flap

VERELAN[®] PM
(Verapamil HCl)
EXTENDED-RELEASE CAPSULES
300 mg
Controlled-Onset

NDC 0091-4087-99
5-1 x 3 Capsules

Professional Sample

VERELAN[®] PM

Verapamil HCl

EXTENDED-RELEASE CAPSULES

300 mg

CONTROLLED-ONSET

Rx Only

Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F)

[See USP Controlled Room Temperature]

Protect from moisture.

See package insert for further information.

Manufactured for:

SCHWARZ PHARMA, INC. (logo)

Milwaukee, WI 53201

By:



Eli Lilly, Inc.
Pharmaceutical Division
Greenfield, IN 46030

CR3815 10/98

©1998, Schwarz Pharma, Inc., Milwaukee WI 53201, USA

Side Panel

Back Panel

000039